Literature DB >> 25488786

Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.

Denis Poddubnyy1, Lianne S Gensler2.   

Abstract

In spondyloarthritis (SpA), spontaneous remission is best described in reactive arthritis, a form of peripheral SpA. Prior SpA observational studies suggested that a significant percentage of patients reached spontaneous remission; however, these patients were followed up under older, broader European Spondyloarthropathy Study Group (ESSG) criteria or were not defined by specific criteria. In general, they were mixed populations of peripheral and axial disease, and the subsets were not differentiated when assessing end points such as remission. There are limited data on the natural history of axial SpA, in part because of the evolution of the criteria with the more recently developed Assessment of SpondyloArthritis International Society (ASAS) criteria, including the designation of non-radiographic axial SpA and peripheral SpA. Clinical trials have been conducted with various remission end points including withdrawal of therapy to determine remission maintenance. The following review addresses the potential for remission in axial and peripheral SpA based on the data from both observational studies and clinical trials.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Peripheral spondyloarthritis; Reactive arthritis; Remission; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25488786      PMCID: PMC4289210          DOI: 10.1016/j.berh.2014.10.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  56 in total

1.  Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?

Authors:  Uta Kiltz; Xenofon Baraliakos; Pantelis Karakostas; Manfred Igelmann; Ludwig Kalthoff; Claudia Klink; Dietmar Krause; Elmar Schmitz-Bortz; Martina Flörecke; Matthias Bollow; Jürgen Braun
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis.

Authors:  Denis Poddubnyy; Martin Rudwaleit; Hildrun Haibel; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2011-05-27       Impact factor: 19.103

Review 3.  Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis.

Authors:  Claire E Barber; Joseph Kim; Robert D Inman; John M Esdaile; Matthew T James
Journal:  J Rheumatol       Date:  2013-04-15       Impact factor: 4.666

4.  Factors associated with attrition in a longitudinal rheumatoid arthritis registry.

Authors:  Christine K Iannaccone; Anne Fossel; Hsun Tsao; Jing Cui; Michael Weinblatt; Nancy Shadick
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-07       Impact factor: 4.794

5.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.

Authors:  Ejaz Pathan; Sonya Abraham; Elizabeth Van Rossen; Robin Withrington; Andrew Keat; Peter J Charles; Erin Paterson; Muslima Chowdhury; Catherine McClinton; Peter C Taylor
Journal:  Ann Rheum Dis       Date:  2012-09-14       Impact factor: 19.103

6.  Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study.

Authors:  Terhi M Uotila; Jaakko A Antonen; Antti S Paakkala; Jukka T Mustonen; Markku M Korpela
Journal:  Clin Rheumatol       Date:  2013-04-05       Impact factor: 2.980

7.  Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.

Authors:  In-Ho Song; Anja Weiß; Kay-Geert A Hermann; Hildrun Haibel; Christian E Althoff; Denis Poddubnyy; Joachim Listing; Ekkehard Lange; Bruce Freundlich; Martin Rudwaleit; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

8.  Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.

Authors:  Jacqueline E Paramarta; Leen De Rycke; Tanja F Heijda; Carmen A Ambarus; Koen Vos; Huib J Dinant; Paul P Tak; Dominique L Baeten
Journal:  Ann Rheum Dis       Date:  2012-11-08       Impact factor: 19.103

9.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

Authors:  Joachim Sieper; Désirée van der Heijde; Maxime Dougados; Philip J Mease; Walter P Maksymowych; Matthew A Brown; Vipin Arora; Aileen L Pangan
Journal:  Ann Rheum Dis       Date:  2012-07-07       Impact factor: 19.103

10.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

View more
  8 in total

Review 1.  [Tapering and termination of immunosuppressive treatment in spondyloarthritides (including psoriatic arthritis)].

Authors:  G Scholz; B Möller
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

2.  Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission.

Authors:  Xiaochan Chen; Ting Zhang; Wenwen Wang; Jing Xue
Journal:  Clin Rheumatol       Date:  2018-04-18       Impact factor: 2.980

Review 3.  Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia.

Authors:  Hanan Al Rayes; Mansour Alazmi; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi; Suzan Attar
Journal:  Clin Rheumatol       Date:  2022-01-08       Impact factor: 2.980

4.  Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.

Authors:  Hatice Bodur; Fatma Gul Yurdakul; Sebnem Ataman; Hasan Fatih Cay; Gulcan Gurer; Erhan Capkin; İlhan Sezer; Mehmet Tuncay Duruoz; Meltem Alkan Melikoglu; Aylin Rezvani; Ilker Yagci; Feride Gogus; Ayhan Kamanli; Ozgur Akgul; Remzi Cevik
Journal:  Clin Rheumatol       Date:  2022-03-30       Impact factor: 2.980

5.  A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Authors:  Atul Deodhar; Lianne S Gensler; Jonathan Kay; Walter P Maksymowych; Nigil Haroon; Robert Landewé; Martin Rudwaleit; Stephen Hall; Lars Bauer; Bengt Hoepken; Natasha de Peyrecave; Brian Kilgallen; Désirée van der Heijde
Journal:  Arthritis Rheumatol       Date:  2019-05-28       Impact factor: 10.995

6.  Ultrasound-guided epidural block in axial spondyloarthritis patients with limited spine mobility: a randomized controlled trial.

Authors:  A M Elsaman; A Hamed; A R Radwan
Journal:  Korean J Pain       Date:  2021-01-01

Review 7.  A glance into the future of diagnosis and treatment of spondyloarthritis.

Authors:  Victoria Navarro-Compán; Joerg Ermann; Denis Poddubnyy
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-07-22       Impact factor: 3.625

8.  Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.

Authors:  Laura Pina Vegas; Emilie Sbidian; Daniel Wendling; Philippe Goupille; Salah Ferkal; Philippe Le Corvoisier; Bijan Ghaleh; Alain Luciani; Pascal Claudepierre
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.